XML 43 R30.htm IDEA: XBRL DOCUMENT v3.24.0.1
INVESTMENTS (Tables)
 12 Months Ended
Dec. 31, 2023
Investments, All Other Investments [Abstract]  
Schedule of Cash and Financial Assets Measured at Fair Value on a Recurring Basis
The following tables present the Company’s cash and financial assets that are measured at fair value on a recurring basis for each of the hierarchy levels (in thousands):
December 31, 2023
CostUnrealized
Gains		Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents, excluding money market accounts
$88,778 $— $— $88,778 $88,778 $— 
Level 1:
Money market accounts5,662 — — 5,662 5,662 — 
Government & agency securities15,282 126 40 15,448 — 15,448 
Equity securities
10,000 150 — 10,150 — 10,150 
30,944 276 40 31,260 5,662 25,598 
Level 2:
Corporate bonds
29,440 293 270 30,003 — 30,003 
Total$149,162 $569 $310 $150,041 $94,440 $55,601 
December 31, 2022
CostUnrealized
Gains		Accrued
Interest		Estimated
Fair Value		Cash & Cash
Equivalents		Investment
Securities
Cash and cash equivalents$87,691 $— $— $87,691 $87,691 $— 
Total$87,691 $— $— $87,691 $87,691 $— 
Summary of Investment Gains The gains related to the Company's LifeMD investment for the year ended December 31, 2023, 2022 and 2021 are summarized in the table below (in thousands):
December 31, 2023December 31, 2022December 31, 2021
Net gains recognized during the period on equity securities
$150 $— $— 
Less: Net gains recognized on equity securities sold
— — — 
Unrealized gains recognized during the reporting period on equity securities still held at the reporting date
$150 $— $—